Compounds > jbp 485
Page last updated: 2024-12-11

jbp 485

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

JBP 485: has antihepatitis activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9815587
CHEMBL ID2229108
MeSH IDM0368378

Synonyms (9)

Synonym
jbp 485
jbp485
CHEMBL2229108 ,
cyclo-trans-4-l-hydroxyprolyl-l-serine
211868-63-2
(3s,7r,8as)-hexahydro-7-hydroxy-3-(hydroxymethyl)-pyrrolo[1,2-a]pyrazine-1,4-dione
(3s,7r,8as)-7-hydroxy-3-(hydroxymethyl)-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
bdbm50519220
DTXSID701043599

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The purpose of this study was to investigate the pharmacokinetic mechanism of interaction between JBP485 (cyclo-trans-4-L-hydroxyprolyl-L-serine, a dipeptide) and cephalexin when they were coadministered in rats."( Pharmacokinetic interaction between JBP485 and cephalexin in rats.
Cang, J; Gao, Y; Kaku, T; Liu, K; Liu, Q; Meng, Q; Sun, H; Wang, C; Zhang, J, 2010)		0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" We aimed to elucidate whether entecavir was a substrate of OAT1, OAT3, OCT, and PEPT1 and to investigate the targets of drug-drug interactions between entecavir and JBP485."( OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485.
Kaku, T; Liu, K; Liu, Q; Ma, X; Meng, Q; Peng, J; Sun, H; Wang, C; Xu, Q, 2013)		0.39

Bioavailability

ExcerptReferenceRelevance
"05 l/kg and bioavailability was about 30% at a dosage of 25 mg/kg."( Pharmacokinetics and mechanism of intestinal absorption of JBP485 in rats.
Cang, J; Kaku, T; Liu, K; Liu, Q; Meng, Q; Sugiyama, Y; Tsuji, A; Wang, C; Wang, D; Zhang, J, 2010)		0.36
" Previous experiments in rats showed that JBP485 was well absorbed by the intestine after oral administration."( Uptake, transport and regulation of JBP485 by PEPT1 in vitro and in vivo.
Cang, J; Kaku, T; Liu, K; Liu, Q; Liu, Z; Mei, L; Meng, Q; Wang, C, 2011)		0.37
" However, oral bioavailability of JBP485 is limited due to the impaired absorptive function during intestinal injury."( Resveratrol enhances the protective effects of JBP485 against indomethacin-induced rat intestinal damage in vivo and vitro through up-regulating oligopeptide transporter 1 (Pept1).
Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Shu, R; Sun, H; Sun, P; Wang, C; Wu, J, 2019)		0.51

Dosage Studied

ExcerptRelevanceReference
"05 l/kg and bioavailability was about 30% at a dosage of 25 mg/kg."( Pharmacokinetics and mechanism of intestinal absorption of JBP485 in rats.
Cang, J; Kaku, T; Liu, K; Liu, Q; Meng, Q; Sugiyama, Y; Tsuji, A; Wang, C; Wang, D; Zhang, J, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)18,200.00000.18000.19000.2000AID1577451
Solute carrier family 15 member 1Homo sapiens (human)Ki36,000.00000.18003.39339.8000AID1577473
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID1577424Half life in pH 5.8 phosphate buffer at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877456Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in steatosis at 30 to 100 mg/kg checked in presence of vitamin E by H and E staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577450Substrate activity at PEPT1 in human Caco2 cells assessed as Km measured after 10 mins by Eadie-Hofstee plot analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577447Substrate activity at OCT1 in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in presence of OCT1 substrate metformin by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577455AUC (0 to t) in Sprague-Dawley rat at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577448Substrate activity at OCT3 in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in absence of OCT1 substrate metformin by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1082823Toxicity in Artemia salina (brine shrimp) at 28 degC after 48 hr2012Journal of agricultural and food chemistry, Apr-04, Volume: 60, Issue:13
Metabolites from Aspergillus fumigatus, an endophytic fungus associated with Melia azedarach, and their antifungal, antifeedant, and toxic activities.
AID1577459Oral bioavailability in Sprague-Dawley rat at 12 mg/kg by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877452Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver ballooning degeneration at 100 mg/kg by H and E staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877487Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in total cholesterol level at 30 mg/kg checked in presence of vitamin E2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577440Ratio of compound effect for substrate activity at PEPT1 in Sprague-Dawley rat jejunum assessed as effective permeability in absence of non-metabolized PEPT1 substrate Gly-Sar to compound effect for substrate activity at PEPT1 in Sprague-Dawley rat jejunu2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577453Cmax in Sprague-Dawley rat at 6 mg/kg, iv by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577442Substrate activity at PEPT1 in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in pH 7.4 HBSS buffer by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877453Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver lobular inflammation at 100 mg/kg by H and E staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877460Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse at 30 to 100 mg/kg checked in presence of vitamin E by Oil red-O staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577505Terminal half life in Sprague-Dawley rat assessed as JBP485 level at 100 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577425Half life in pH 6.8 phosphate buffer at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577457Tmax in Sprague-Dawley rat at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577509Cmax in Sprague-Dawley rat assessed as JBP485 level at 12 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577431Half life in Sprague-Dawley rat plasma at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577468Terminal half life in Beagle dog at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577488Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in serum alanine aminotransferase level at 6.25 to 25 mg/kg, po administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 46 2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577422Half life in 0.1 M HCl at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877446Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver index at 100 mg/kg2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577429Half life in Sprague-Dawley rat intestinal homogenates at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877481Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in total cholesterol level at 100 mg/kg administered for 14 days2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877488Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in malondialdehyde level at 100 mg/kg administered for 14 days2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877454Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver fibrosis at 100 mg/kg by sirius red staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577504Cmax in Sprague-Dawley rat assessed as JBP485 level at 100 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577456Cmax in Sprague-Dawley rat at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577479Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in hepatocellular edema at 6.25 to 25 mg/kg, po administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 46 hrs post ANIT ch2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577438Substrate activity at PEPT1 in Sprague-Dawley rat jejunum assessed as effective permeability at 5 mM measured after 15 to 120 mins by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577506Tmax in Sprague-Dawley rat assessed as JBP485 level at 100 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577478Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in liver necrosis at 6.25 to 25 mg/kg, po administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 46 hrs post ANIT challeng2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577452AUC (0 to t) in Sprague-Dawley rat at 6 mg/kg, iv by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577426Half life in pH 7.2 phosphate buffer at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577458Terminal half-life in Sprague-Dawley rat at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577467Tmax in Beagle dog at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877486Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in triglyceride level at 30 mg/kg checked in presence of vitamin E2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877451Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in steatosis at 100 mg/kg by H and E staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577449Substrate activity at OCT3 in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in presence of OCT1 substrate metformin by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877480Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in triglyceride level at 100 mg/kg administered for 14 days2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577483Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in serum aspartate aminotransferase level at 6.25 to 12.5 mg/kg, ip administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577427Half life in pH 1.2 simulated gastric fluid at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577430Half life in Sprague-Dawley rat liver homogenates at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577482Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in serum alanine aminotransferase level at 6.25 to 12.5 mg/kg, ip administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 42019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877473Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in serum ALT level at 30 to 100 mg/kg checked in presence of vitamin E2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877478Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in LDH level at 100 mg/kg checked in presence of vitamin E2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577444Substrate activity at OATPB in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in absence of OATPB substrate estrone-3-sulfuric acid by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877497Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as decrease in IFN expression at 100 mg/kg checked in presence of vitamin E by flow cytometry2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577477Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in hepatocellular edema at 6.25 to 12.5 mg/kg, ip administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 46 hrs post ANIT 2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577485Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in serum aspartate aminotransferase level at 6.25 to 25 mg/kg, po administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 42019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577435Apparent permeability across human Caco2 cells at 0.5 mM measured after 5 to 60 mins by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577454Terminal half-life in Sprague-Dawley rat at 6 mg/kg, iv by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577507AUC (0 to t) in Sprague-Dawley rat assessed as JBP485 level at 12 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577446Substrate activity at OCT1 in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in absence of OCT1 substrate metformin by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577502AUC (0 to t) in Sprague-Dawley rat assessed as JBP485 level at 100 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577436Bioavailability in Wistar rat at 6.25 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877457Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver ballooning degeneration at 30 to 100 mg/kg checked in presence of vitamin E by H and E staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577466Cmax in Beagle dog at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577443Substrate activity at PEPT1 in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in pH 6 HBSS buffer in presence of non-metabolized PEPT1 substrate Gly-Sar by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877491Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in malondialdehyde level at 30 mg/kg checked in presence of vitamin E2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577451Substrate activity at PEPT1 in human Caco2 cells assessed as inhibition of Gly-Sar uptake measured after 10 mins by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577490Anti-hepatitis activity in ANIT-induced ip dosed Sprague-Dawley rat model of cholestasis assessed as reduction in serum total bilirubin level administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 46 hrs post ANIT challenge a2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577508Tmax in Sprague-Dawley rat assessed as JBP485 level at 12 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877474Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in serum AST level at 30 to 100 mg/kg checked in presence of vitamin E2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577428Half life in pH 6.8 simulated intestinal fluid at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577473Substrate activity at PEPT1 in human Caco2 cells assessed as inhibition of Gly-Sar uptake by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877455Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse at 100 mg/kg by Oil red-O staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577510Terminal half life in Sprague-Dawley rat assessed as JBP485 level at 12 mg/kg, po by LC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877459Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver fibrosis at 30 to 100 mg/kg checked in presence of vitamin E by sirius red staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877495Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as decrease in IL-2 expression at 30 mg/kg checked in presence of vitamin E by flow cytometry2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577465AUC (0 to t) in Beagle dog at 12 mg/kg, po by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577441Substrate activity at PEPT1 in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in pH 6 HBSS buffer by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1877447Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver index at 30 to 100 mg/kg checked in presence of 60 mg/kg vitamin E2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877496Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as decrease in IL-17A expression at 30 mg/kg checked in presence of vitamin E by flow cytometry2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1877458Anti-NASH activity in CCl4-induced nonalcoholic steatohepatitis C57BL mouse assessed as reduction in liver lobular inflammation at 30 to 100 mg/kg checked in presence of vitamin E by H and E staining based assay2022Bioorganic & medicinal chemistry letters, 01-15, Volume: 56Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH.
AID1577423Half life in pH 4.5 acetate buffer at 5 mM by HPLC analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577445Substrate activity at OATPB in human Caco2 cells assessed as protein-mediated drug uptake at 0.5 mM measured after 10 mins in presence of OATPB substrate estrone-3-sulfuric acid by UPLC-MS/MS analysis2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577476Anti-hepatitis activity in ANIT-induced Sprague-Dawley rat model of liver injury assessed as reduction in liver necrosis at 6.25 to 12.5 mg/kg, ip administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 46 hrs post ANIT challe2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
AID1577491Anti-hepatitis activity in ANIT-induced po dosed Sprague-Dawley rat model of cholestasis assessed as reduction in serum total bilirubin level administered 30 mins prior to ANIT challenge and subsequent dosing at 8, 22, 32, and 46 hrs post ANIT challenge a2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Bioactivatable Pseudotripeptidization of Cyclic Dipeptides To Increase the Affinity toward Oligopeptide Transporter 1 for Enhanced Oral Absorption: An Application to Cyclo(l-Hyp-l-Ser) (JBP485).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (12.00)29.6817
2010's21 (84.00)24.3611
2020's1 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.16 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		2.0710pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
p-aminohippuric acid
p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.		2.0710N-acylglycineDaphnia magna metabolite
diethyl pyrocarbonate
Diethyl Pyrocarbonate: Preservative for wines, soft drinks, and fruit juices and a gentle esterifying agent.. diethyl pyrocarbonate : The diethyl ester of dicarbonic acid.		2.0610acyclic carboxylic anhydride
gentamicin
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.		2.0810
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.5220aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		2.0710benzoic acids;
sulfonamide		uricosuric drug
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.4110chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		2.0710amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
gluconic acid
gluconic acid: zinc gluconate has anti-inflammatory activity; RN given refers to (D)-isomer; all RRs refers to (D)-isomer unless otherwise noted. ketogluconic acid : A gluconic acid that contains a ketonic carbonyl group.. D-gluconic acid : A gluconic acid having D-configuration.		2.0610gluconic acidchelator;
Penicillium metabolite
copper gluconate
Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.		2.0610organic molecular entity
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.0810dialdehydebiomarker
1-naphthylisothiocyanate
1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.		2.4320isothiocyanateinsecticide
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.1710glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
glycyrrhizic acid
glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.		210enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		2.4110alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
hymexazol
hymexazol: a chemical used to sterilize soil; structure in first source. hymexazol : A member of the class of isoxazoles carrying hydroxy and methyl substituents at positions 3 and 5 respectively. It is used worldwide as a systemic soil and seed fungicide for the control of diseases caused by Fusarium, Aphanomyces, Pythium, and Corticium spp. in rice, sugarbeet, fodderbeet, vegetables, cucurbits, and ornamentals.		2.0710heteroaryl hydroxy compound;
isoxazoles		antifungal agrochemical
carbendazim
carbendazim: carcinogen when combined with sodium nitrite; principle metabolite of thiophanate methyl & benomyl; structure. carbendazim : A member of the class of benzimidazoles that is 2-aminobenzimidazole in which the primary amino group is substituted by a methoxycarbonyl group. A fungicide, carbendazim controls Ascomycetes, Fungi Imperfecti, and Basidiomycetes on a wide variety of crops, including bananas, cereals, cotton, fruits, grapes, mushrooms, ornamentals, peanuts, sugarbeet, soybeans, tobacco, and vegetables.		2.0710benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		antifungal agrochemical;
antinematodal drug;
metabolite;
microtubule-destabilising agent
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		2.4720beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
ubenimex
ubenimex: growth inhibitor		2.0710
glycylsarcosine
glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine.		3.3160dipeptide zwitterion;
dipeptide
cyclo(prolylglycyl)
cyclo(prolylglycyl): RN given is for 17O-labeled cpd		2.0710
brevianamide f
brevianamide F: isolated from the endophyte from Aspergillus fumigatus associated with Melia azedarach L that could be used to develop a natural eco-friendly herbicide.structure in first source. brevianamide F : A pyrrolopyrazine that is hexahydropyrrolo[1,2-a]pyrazine-1,4-dione bearing an indol-3-ylmethyl substituent at position 3 (the 3S,8aS-diastereomer, obtained by formal cyclocondensation of L-tryptophan and L-proline).		2.0710dipeptide;
indoles;
pyrrolopyrazine		metabolite
tryptoquivaline
fumitremorgin C : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi. A potent and specific inhibitor of the breast cancer resistance protein multidrug transporter.		2.0710aromatic ether;
indole alkaloid;
organic heteropentacyclic compound		breast cancer resistance protein inhibitor;
mycotoxin
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		2.2110resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
helvolic acid
helvolic acid: structure. helvolic acid : A steroid C-21 acid having a 29-nordammarane skeleton substituted with an acetoxy group at C-16 and oxo groups at C-3 and -7, with double bonds at C-1, -17(20) and -24.		2.07103-oxo-Delta(1) steroid;
acetate ester;
monocarboxylic acid;
steroid acid		antibacterial agent;
fungal metabolite;
mycotoxin
bilirubin
[no description available]		2.0710biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		2.0810D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		2.7730dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
pseurotin
pseurotin: metabolite isolated from culture filtrates of Pseudeurotium ovalis Stolk; structure. pseurotin A : A spirocyclic that is 1-oxa-7-azaspiro[4.4]non-2-ene-4,6-dione bearing 1,2-dihydroxyhex-3-en-1-yl, methyl, methoxy, benzoyl and hydroxy substituents at positions 2, 3, 8, 8 and 9 respectively.		2.0710azaspiro compound;
lactam;
oxaspiro compound		metabolite
toosendanin
[no description available]		2.0710limonoid
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.4820aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
tryprostatin a
tryprostatin A: isolated from Aspergillus fumigatus; a mammalian cell cycle inhibitor; structure given in first source. tryprostatin A : A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and methoxy groups respectively.		2.0710aromatic ether;
dipeptide;
indole alkaloid;
indoles;
pyrrolopyrazine		breast cancer resistance protein inhibitor
fumiquinazoline f
fumiquinazoline F: structure in first source. fumiquinazoline F : A fumiquinazoline that consists of pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione bearing a methyl substituent at position 1 and an indol-3-yl group at position 4.		2.0710fumiquinazoline;
indoles;
pyrazinoquinazoline
(S)-Isosclerone
[no description available]		2.0710tetralins
fumiquinazoline a
fumiquinazoline A: structure in first source. fumiquinazoline A : A fumiquinazoline that consists of imidazoindole and pyrazinoquinazoline units connected by a methylene group.		2.0710fumiquinazoline;
imidazoindole;
pyrazinoquinazoline
6-methoxyspirotryprostatin b
6-methoxyspirotryprostatin B: cytotoxic compound from the marine-derived fungus Aspergillus sydowi; structure in first source. 6-methoxyspirotryprostatin B : An indole alkaloid isolated from a marine-derived fungal strain Aspergillus sydowii PFW1-13 and has been shown to exhibit cytotoxic activity.		2.0710aromatic ether;
azaspiro compound;
indole alkaloid;
indolones		antineoplastic agent;
Aspergillus metabolite
entecavir
entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.		2.08102-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.07102-aminopurines;
oxopurine		antimetabolite;
antiviral drug
guanine
[no description available]		2.08102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		2.4520
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Liver Injury, Drug-Induced
[description not available]		02.7430
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.7430
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.4110
Fatty Liver, Nonalcoholic
[description not available]		02.4110
Cirrhosis
[description not available]		02.4110
Innate Inflammatory Response
[description not available]		02.4110
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.4110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.4110
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.4110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5420
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.1710
Acute Kidney Failure
[description not available]		02.4820
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		02.4820
Dry Eye
[description not available]		02.1110
Dry Eye Syndromes
Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.		02.1110
Jaundice, Cholestatic
[description not available]		02.0710
Jaundice, Obstructive
Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.		02.0710